Key Studies in Genitourinary Cancers: Independent Conference Coverage of the 2020 ASCO Virtual Scientific Meeting
  • CME

May 29-31, 2020; Online at meetings.asco.org/am
Daniel P. Petrylak, MD, and Elizabeth R. Plimack, MD, MS, discuss the most clinically relevant data in renal cell carcinoma, urothelial carcinoma, and prostate cancer presented at ASCO 2020 in this expert analysis.
Daniel P. Petrylak, MD
Elizabeth R. Plimack, MD, MS
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: September 1, 2020 Expiration: August 31, 2021

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with genitourinary cancers.
  • Identify subpopulations of patients with genitourinary cancers most likely to benefit from a specific treatment plan based on prognostic or predictive markers
  • Discuss new data on novel agents and therapeutic approaches for patients with genitourinary cancers
  • Consider how new trial findings might affect treatment of genitourinary cancers and clinical practice in the future

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Exelixis
Pfizer and EMD Serono, Inc.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Daniel P. Petrylak, MD

Professor of Medicine, Medical Oncology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Group
Yale Cancer Center
New Haven, Connecticut

Daniel P. Petrylak, MD, has disclosed that he has received consulting fees from Ada Cap (Advanced Accelerator Applications), Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Exelixis, Incyte, Janssen, Lilly, Pfizer, Pharmacyclics, Roche Laboratories, Seattle Genetics, and UroGen Pharma; has received funds for research support from Ada Cap (Advanced Accelerator Applications), Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Clovis, Endocyte, Genentech, Innocrin, Lilly, MedImmune, Merck, Novartis, Pfizer, Progenics, Roche Laboratories, Sanofi, and Seattle Genetics; and holds ownership interests with Bellicum and Tyme.
Elizabeth R. Plimack, MD, MS

Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania

Elizabeth R. Plimack, MD, MS, has disclosed that she has received funds for research support from AstraZeneca, Bristol-Myers Squibb, Genentech, Merck, Peloton, and Pfizer and consulting fees from AstraZeneca, Bristol-Myers Squibb, Genentech, Incyte, Janssen, Merck, and Pfizer.

Staff

Kristen Rosenthal, PhD

Senior Scientific Director

Kristen M. Rosenthal, PhD, has no relevant conflicts of interest to report.
Anna Poppa

Editorial Contributor

Anna Poppa has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Krista Marcello

Associate Director, Educational Strategy

Krista Marcello has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason Everly, PharmD, has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has disclosed that his spouse/partner has received salary from and holds ownership interests with AstraZeneca.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with genitourinary cancers.

Goal

The goal of this activity is to improve learners’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with genitourinary cancers.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 01, 2020, through August 31, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Downloadable slideset with key data from the 2020 ESMO Virtual Congress created by Clinical Care Options (CCO)

Yelena Y. Janjigian, MD Joyce O'Shaughnessy, MD Elizabeth R. Plimack, MD, MS person default Vamsidhar Velcheti, MD Released: October 23, 2020

From Clinical Care Options (CCO), an on-demand Webcast with Daniel Petrylak, MD, and other experts on optimal treatment for urothelial carcinoma

Matthew I. Milowsky, MD Daniel P. Petrylak, MD Jonathan E. Rosenberg, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Physician Assistants: maximum of 1.25 hours of AAPA Category I (Preapproved) credits Pharmacists: 1.25 contact hours (0.125 CEUs) Released: October 19, 2020 Expired: October 18, 2021

Downloadable slides on biomarker testing in patients with ovarian cancer from Clinical Care Options (CCO)

Prof Nicolette Colombo Bradley J. Monk, MD, FACS, FACOG Released: October 9, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue